05B4 Hyslop, Terry - Jefferson Medical College - Thomas Jefferson University
tmh102

Terry Hyslop, PhD

Contact Dr. Hyslop

1015 Chestnut Street
Suite M-100 Mezzanine
Philadelphia, PA 19107

(215) 503-7806
(215) 503-3804 fax

Most Recent Peer-reviewed Publications

  1. A phase i study of the combination of sorafenib with temozolomide and radiation therapy for the treatment of primary and recurrent high-grade gliomas
  2. Early results of prostate cancer radiation therapy: An analysis with emphasis on research strategies to improve treatment delivery and outcomes
  3. A Dual-Institution Randomized Controlled Trial of Remnant Closure after Distal Pancreatectomy: Does the Addition of a Falciform Patch and Fibrin Glue Improve Outcomes?
  4. Circadian Gene Expression and Clinicopathologic Correlates in Pancreatic Cancer
  5. Low levels of Stat5a protein in breast cancer are associated with tumor progression and unfavorable clinical outcomes
  6. Prognostic factors and outcomes after definitive treatment of female urethral cancer: A population-based analysis
  7. Epidermal growth factor receptor and insulinlike growth factor 1 receptor expression predict poor survival in pancreatic ductal adenocarcinoma
  8. Analytic lymph node number establishes staging accuracy by occult tumor burden in colorectal cancer
  9. GUCY2C molecular staging personalizes colorectal cancer patient management
  10. Occult tumor burden contributes to racial disparities in stage-specific colorectal cancer outcomes
  11. Genetic Variations in Stem Cell-Related Genes and Colorectal Cancer Prognosis
  12. Molecular staging individualizing cancer management
  13. c-Myb and its target Bmi1 are required for p190BCR/ABL leukemogenesis in mouse and human cells
  14. GUCY2C opposes systemic genotoxic tumorigenesis by regulating AKT-dependent intestinal barrier integrity
  15. Lymph node ratio is an important and independent prognostic factor for patients with stage III melanoma
  16. Comparative effectiveness research for prostate cancer radiation therapy: Current status and future directions
  17. A phase 1b trial of the combination of the antiangiogenic agent sunitinib and radiation therapy for patients with primary and metastatic central nervous system malignancies
  18. Reply to A. Italiano
  19. Harmonization of regulatory approaches for evaluating therapeutic equivalence and interchangeability of multisource drug products: Workshop summary report
  20. Serum monocyte chemoattractant protein-1 in pancreatic cancer
0